LSL Pharma Group Announces Brokered Private Placement of Convertible Debentures of Up to $4,000,000
LSL Pharma Group Announces Brokered Private Placement of Convertible Debentures of Up to $4,000,000
Debenture proceeds will provide additional funds and flexibility for growth
債券收益將為增長提供額外的資金和靈活性
BOUCHERVILLE, Québec, Sept. 21, 2023 (GLOBE NEWSWIRE) -- LSL Pharma Group Inc. (TSXV: LSL) – (the "Company" or "LSL Pharma Group"), a Canadian integrated pharmaceutical company, announced today that it has entered into an agreement with iA Capital Markets as the sole agent and sole bookrunner ("Agent"), in connection with a "best-efforts" brokered private placement offering of up to $4.0 million in unsecured convertible debentures (the "Debentures") of the Company at a price of $10 per convertible debenture, to raise aggregate gross proceeds between $2.0 million and $4.0 million (the "Offering").
鮑切維爾，QuéBEC，9月2023年21日(環球社)--LSL醫藥集團(TSXV：LSL)-(The“The”公司“或”LSL醫藥集團加拿大綜合藥業公司)今天宣佈，已與作為獨家代理及獨家賬簿管理人(“代理”)的IA Capital Markets訂立協定，就本公司“盡最大努力”經紀私募發行高達400萬美元的無抵押可轉換債券(“債券”)，每張可轉換債券的價格為10美元，以籌集合共200萬至400萬美元的總收益。供奉“)。
The Debentures will be convertible into Class A shares of the capital stock of the Company (the "Class A Shares") at the option of the holder at any time prior to the close of business on the earlier of: (i) the last business day immediately preceding the Maturity Date, and (ii) the date fixed for redemption, at a conversion price of $0.70 per Class A Share (the "Conversion Price"), subject to adjustment in certain events.
債券將可轉換為本公司股本的A類股份(“A類股)在以下日期之前的任何時間，持有人有選擇權：(I)緊接到期日之前的最後一個營業日，及(Ii)定出的贖回日期，換股價格為每股A類股0.70元(折算價格“)，在某些情況下可作調整。
The Debentures will mature 5 years from the Closing Date and accrue interest from the Closing Date at a rate of 11% per annum (the "Base Rate"), compounded semi-annually on the last day of April and October of each year. Interest will be payable in cash semi-annually on the last day of April and October, with payments commencing April 30, 2025. The annual interest rate will be recalculated on April 30 of every year, starting April 30, 2025 (each an "Interest Rate Review Date"), and will be equal to the Base Rate less 100 basis points for each Business Objective achieved (as defined below).
債券將於截止日期起計5年期滿，並於截止日期起計息，年利率為11%(“基本費率)，每半年複利一次，在每年4月和10月的最後一天支付。利息每半年在4月和10月的最後一天以現金支付一次，從2025年4月30日開始支付。年利率將於每年的4月30日重新計算，從2025年4月30日開始(每隔一年利率檢討日期“)，並將等於實現每項業務目標的基本利率減去100個基點(定義如下)。
Business Objectives (each a "Business Objective"):
業務目標(每個目標都是“業務目標“)：
| 1) | The Company will obtain FDA approval for its Steri-Med plant (one-time business objective); | ||
| 2) | The Company will complete the acquisition of a business that: (i) complements the Company's existing product offering and/or will create synergies with the Company's existing business operations; and (ii) generated a minimum of $5.0 million in revenue during the last twelve-month period preceding the acquisition (one-time business objective); and | ||
| 3) | The Company will generate a minimum of $30 million of revenue with a 20% EBITDA margin during the fiscal period preceding the Interest Rate Review Date (annual business objective). |
| 1) | 該公司的Steri-Med工廠將獲得FDA的批准(一次性業務目標)； | ||
| 2) | 公司將完成對以下業務的收購：(I)補充公司現有的產品供應和/或將與公司現有的業務運營產生協同效應；和(Ii)在收購前12個月內產生至少500萬美元的收入(一次性業務目標)；和 | ||
| 3) | 在利率審查日期(年度業務目標)之前的會計期間，該公司將產生至少3000萬美元的收入，EBITDA利潤率為20%。 |
If, at any time following the date that is 24 months from the Closing Date, for the preceding 20 consecutive trading days (i) the daily volume weighted average trading price of the Class A Shares on the TSX Venture Exchange (the "TSXV") is greater than 175% of the Conversion Price; and (ii) the average daily volume of the Class A Shares traded on the TSXV is no less than the number obtained when dividing the number of shares issued upon conversion of the total amount of Debentures outstanding by twenty (20), the Company shall have the option to convert all of the principal amount outstanding of the Debentures at the Conversion Price with at least 30 days' prior written notice.
如果在成交日起24個月後的任何時間，連續20個交易日內(I)多倫多證券交易所創業板A類股的日成交量加權平均交易價(“TSXV“)超過換股價的175%；及(Ii)在多倫多證券交易所買賣的A類股份每日平均成交量不少於轉換已發行債券總數除以二十(20)後所得的數目，則本公司有權在至少30日前發出書面通知，按換股價兌換債券的全部已發行本金。
The Agent further shall have the option, exercisable at any time up to two days prior to the closing of the Offering, to increase the size of the Offering by up to $1.0 million (the "Agent's Option"). Assuming the full exercise of the Agent's Option, the aggregate gross proceeds of the Offering will be $5 million.
代理人還有權在發售結束前兩天內隨時行使選擇權，將發售規模增加最多100萬美元(“代理的選項“)。假設代理人的選擇權全部行使，發售的總收益總額將為500萬美元。
The net proceeds of the Offering will be used for working capital, capital expenditures, and for general corporate purposes.
此次發行的淨收益將用於營運資本、資本支出和一般企業用途。
For its services in connection with the Offering, the Company will pay to the Agent: (i) a cash commission equal to 7% of all gross proceeds raised in connection with the Offering from purchasers not included on the President's List; (ii) a cash fee equal to 1.0% of all gross proceeds raised in connection with the Offering from purchasers identified by the Company (the "President's List"); and (iii) broker warrants of the Company ("Broker Warrants") equal to 7.0% of the gross proceeds of the Offering from purchasers not included on the President's List and 1.0% of the gross proceeds of the Offering from purchasers on the President's List divided by the Conversion Price, at an exercise price equal to the Conversion Price. The Broker Warrants will be exercisable to acquire one Class A Share of the Company for a period of 24 months from the date of issuance of the Broker Warrants.
就其與發售有關的服務，本公司將向代理人支付：(I)相當於非總裁名單上所列買家與發售有關的所有總收入的7%的現金佣金；(Ii)相當於本公司指認的買家(“本公司”)與發售有關的所有總收入的1.0%的現金佣金。總裁的名單“)；及。(Iii)本公司的經紀認股權證(”經紀人認股權證“)相當於向非總裁名單上的買家發售股份所得款項總額的7.0%及向總裁名單上的買家發售股份所得款項總額的1.0%除以換股價格，行使價相當於換股價。經紀認股權證將可於自經紀認股權證發行日期起計24個月內行使收購本公司一股A類股份的行使價。
The closing of the Offering is subject to the Company obtaining conditional approval to list the Debentures on the TSXV in addition to customary closing conditions and the receipt of all required regulatory approvals, including but not limited to the approval of the TSXV. The securities issuable pursuant to this Offering will be subject to a hold period as set out in National Instrument 45-102 - Resale of Securities. The Company and the Agent are dealing at arm's length.
完成發售須待本公司取得在多倫多證券交易所上市債券的有條件批准，以及常規成交條件及收到所有所需的監管批准，包括但不限於多倫多證券交易所的批准。根據本次發行發行的證券將受國家文書45-102-證券轉售中規定的持有期限制。公司和代理商的交易保持著一定的距離。
The securities issued in connection with the Offering mentioned herein have not been and will not be qualified for sale to the public under applicable Canadian securities laws and, accordingly, any offer and sale of securities in Canada will be made on a basis which is exempt from the prospectus and, when applicable, dealer registration requirements of such securities laws. Furthermore, none of the securities issued in connection with the Offering will be registered under the United States Securities Act of 1933, as amended (the "1933 Act") or of any other jurisdiction, and none of them may be offered or sold in the United States or in any other jurisdiction absent registration or an applicable exemption from the registration requirements of the 1933 Act or of any other jurisdiction. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
根據適用的加拿大證券法，與本文提及的發售相關發行的證券沒有也不會符合向公眾出售的資格，因此，在加拿大進行的任何證券要約和出售都將在不受招股說明書和(如適用)此類證券法的交易商註冊要求的基礎上進行。此外，與此次發行相關的任何證券都不會根據修訂後的《1933年美國證券法》進行註冊。1933年法案“)或任何其他司法管轄區的任何證券，除非在美國或任何其他司法管轄區進行登記或獲得適用豁免，否則不得在美國或任何其他司法管轄區發售或出售這些證券。本新聞稿不應構成出售要約或徵求購買要約，在任何司法管轄區內，任何此類要約、招攬或出售在根據任何上述司法管轄區的證券法進行登記或資格登記或資格之前是違法的，則不得出售任何此類證券。
Forward-Looking Statements
前瞻性陳述
Information provided and statements contained in this press release that are not purely historical, such as those on the revenue and the EBITDA, are forward-looking statements within the meaning of the applicable securities laws. Certain statements in this press release may constitute forward-looking information within the meaning of securities laws. Forward-looking information may relate to LSL Pharma Group's future outlook and anticipated events, business, operations, financial performance, financial condition or results and, in some cases, can be identified by terminology such as "may"; "will"; "should"; "expect"; "plan"; "anticipate"; "believe"; "intend"; "estimate"; "predict"; "potential"; "continue"; "foresee", "ensure" or other similar expressions concerning matters that are not historical facts. The reader should not place undue importance on forward-looking information and should not rely upon this information as of any other date. LSL Pharma Group will not update these statements unless applicable securities laws require LSL Pharma Group to do so.
本新聞稿中提供的資訊和包含的非純歷史資訊，如有關收入和EBITDA的資訊和陳述，均為適用證券法意義上的前瞻性陳述。本新聞稿中的某些陳述可能構成證券法意義上的前瞻性資訊。前瞻性資訊可能與LSL製藥集團的未來展望和預期事件、業務、運營、財務業績、財務狀況或結果有關，在某些情況下，可以通過“可能”、“將”、“應該”、“預期”、“計劃”、“預期”、“相信”、“打算”、“估計”、“預測”、“潛在”、“繼續”、“預見”、“確保”或與非歷史事實有關的其他類似表述來識別。讀者不應過分重視前瞻性資訊，也不應在任何其他日期依賴這些資訊。LSL醫藥集團不會更新這些聲明，除非適用的證券法要求LSL醫藥集團這樣做。
ABOUT LSL PHARMA GROUP INC.
約 LSL製藥 集團公司
LSL Pharma Group is a Canadian integrated pharmaceutical company specializing in the development, manufacturing and distribution of high-quality natural health products and dietary supplements in solid dosage forms, as well as high quality sterile ophthalmic pharmaceutical products. For more information, please visit and .
LSL Pharma Group是一家加拿大綜合性製藥公司，專門開發、製造和分銷高質量的天然保健品和固體劑型的膳食補充劑，以及高質量的無菌眼科藥品。有關更多資訊，請訪問和。
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
都不是這個多倫多證券交易所 風險投資 交易所 也不是 它的 監管 服務 提供商 (作為 那 術語 是 已定義 在……裡面 中國的政策 這個 多倫多證券交易所風險投資公司 交易所) 承擔責任 為 充分性或 精確度 的 這放手。
CONTACT:
François Roberge, President and Chief Executive Officer
Telephone: 514-664-7700
Email: Investors@groupelslpharma.com
聯繫方式：
FrçOis Roberge、總裁和首席執行官
電話：514-664-7700
電子郵件：Investors@groupelslpharma.com